Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression.
Paolo PreziosaElisabetta PaganiAlessandro MeaniLucia MoiolaMariaemma RodegherMassimo FilippiMaria Assunta RoccaPublished in: Neurology(R) neuroimmunology & neuroinflammation (2022)
This study provides Class III evidence that in patients with RRMS starting treatment with natalizumab or fingolimod, the proportion of SELs on brain MRI was associated with EDSS score worsening and SPMS conversion at 9-year follow-up.